Skip to content

Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B-Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin 2 Type 1 Receptor Antagonist Based Therapy

Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B-Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin 2 Type 1 Receptor Antagonist Based Therapy - Southern Heart Conference Clinical research

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000007101
Enrollment
200
Registered
2012-01-19
Start date
2008-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Sponsors

Southern Heart Conference
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Patients with essential hypertension, who have been previously treated with antihypertensive drugs including ARB for more than 3 months, however, the target blood pressure defined by the guideline for treatment of hypertension has not been achieved 2) Patiens aged 20 to 79 years at the time of the first visit 3) Outpatients 4) Patients who have given written informed consent on use of theie data for the study

Exclusion criteria

Exclusion criteria: 1) Patients with secondary hypertension 2) Patients with cardiac insufficiency (more than NYHA grade II) 3) Patients under treatment with thiazide diuretic 4) Pregnant patients including one trying to conceive pregnancy during the planned study period 5) Patients with severe liver dysfunction 6) Patients with renal failure (serum creatinine ≥2.0 mg/dL) 7) Patients with a history of hypersensitivity to ingredients of losartan and hydrochlorothiazide 8) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 9) Patients who are considered not eligible for the study by the attending doctor due to medical reasons

Design outcomes

Primary

MeasureTime frame
Change and % change in BNP after 12 months of treatment

Secondary

MeasureTime frame
Change and % change in blood pressure after 1,2,3,6,9,12,18,24,30 and 36 months of treatment Change and % change in Uric acid, HbA1c, HDL-C, BNP (excluding values at 12 months), Echocardiography, Electrocardiogram after 3,12,24,30 and 36 months of treatment

Countries

Japan

Contacts

Public ContactHiroshi Meno

Southern Heart Conference secretariat Southern Heart Conference secretariat

092-521-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026